Kornimate/medical-research-clean huggingface dataset:
change in executive function and iadl using a virtual supermarket environment among people with mci

Conditions: Mild Cognitive Impairment; Lack of Physical Activity

Summary: the aim of the study is to investigate the feasibility of using a virtual supermarket as an intervention tool for overcoming deficits in executive function as well as enhancing iadl performance among persons with mild cognitive impairment. the working hypotheses are that there will be improvement in executive functions, and the improvement in the executive functions will result in better performance in instrumental activities of daily living, both generally and especially in shopping task

scientific and clinical research in the area of alzheimer's disease (ad) during the last years have shifted their focus to earlier diagnosis and especially to the transitional phase between normal aging and dementia, named mild cognitive impairment (mci).lately, the concept of mci has been expanded to address observed clinical heterogeneity, and subtypes were recognized: amnestic (including memory impairment) and non-amnestic (including impairment in other non-memory cognitive domains), with the later including deficits in executive functioning executive functions (ef) are defined as higher order functions that are needed for completing complex or non-routine tasks. deficits in ef refer to a collection of deficits in attention, planning, problem-solving, multitasking, monitoring and behavioral control and persons who suffer from impairments in ef typically have difficulty in initiating or suspending activities, show impaired mental flexibility, as well as increased distractibility and have difficulty in learning novel tasks despite apparently intact cognitive abilities. lately, an increasing amount of studies suggest that persons with mci might have deficits in ef, moreover, persons presenting a combination of executive deficits and memory deficits were found to be a high risk group for conversion to ad.

Eligibility criteria:
inclusion criteria: * age 60+ * diagnosed as suffering from mci * no impaired judgement * verbal and written proficiency in hebrew * normal or corrected-to-normal vision and hearing ability * independent in adl function * lives in the community * able to perform task of shopping. exclusion criteria: * suffering from other coexistent neurological diseases (e.g. stroke, muscular dystrophy) * has acute arthritis * poorly controlled hypothyroidism * suffering from physical or sensory limitations, as by self-report or noted by the investigator, that may limit the use of a computer's mouse * no skills in performing shopping task * defined as suffering from depression as determined by the rating scale for depression * diagnosed as suffering from dementia as defined by diagnostic and statistical manual of mental disorders criteria (dsm-iv)

Keywords: mci executive function adl virtual supermarket
outpatient registry trial of respiratory tract infections in adults

Conditions: Pneumonia, Bacterial; Bronchitis, Chronic

Summary: to measure the speed of bacterial eradication from the respiratory tract after administration of azithromycin or telithromycin.

to evaluate the relationship between rate of s. pneumoniae killing in sputum, pk/pd, and clinical response of oral telithromycin and azithromycin in patients with aecb or cap and to determine if there is a difference in the rates of infection site bacterial killing (as described above) between these 3 antibiotics against penicillin- and erythromycin-resistant s.pneumoniae

Eligibility criteria:
inclusion criteria: * adult patients, either males or non-pregnant females, aged 18 to 75 years of age with clinical findings of cap or aecb who are amenable to serial nasopharyngeal and oropharyngeal sampling and having positive binax-now tests indicating infection with streptococcus pneumoniae * patients with a medical history and clinical findings consistent with a respiratory tract infection. a patient with advanced copd, repeated exacerbations by history, a binax-now test consistent with s. pneumoniae and/or proven culture positivity for s. pneumoniae may be enrolled * all patients (cap or aecb) must produce purulent sputum and be positive on the urinary binax-now assay. * the female patient of child bearing potential must agree to use an accepted method of contraception (i.e., oral or implanted contraceptive with a barrier method, spermicide and barrier methods, or iud). the patient must agree to continue with the same method throughout the study. exclusion criteria: * baseline sputum cultures known to be negative for s. pneumoniae, or negative urinary binax-now. * patients with a microbiologically documented pathogen known prior to inclusion to be resistant to any of the study medications. * history of hypersensitivity to macrolides, azalides, ketolide antibiotics or history of serious hypersensitivity reaction to any drug. * pre-existing impaired hepatic function or impaired renal function ccl \<20ml/min * patients who will require on-study treatment with medications known to have contraindicated drug interactions with telithromycin * treatment with more than one dose of an antimicrobial prior to entry into the study others as per protocol

Keywords: pneumonia spneumoniae bronchitis telithromycin azithromycin
application of radiomics in the diagnosis and treatment prediction of pituitary adenoma

Conditions: Pituitary Adenoma

Summary: the images of patients with pituitary adenoma were collected and analyzed based on the methods of radiomics.

inclusion of pituitary adenoma patients diagnosed clinically or pathologically 1. clinical data and pre-treatment imaging data of included patients (dicom format) 2. determine the subtype diagnosis of pituitary adenoma based on the patient's clinical and pathological data 3. collect relevant data of patients before and after treatment 4. using radiomics methods, extract radiomic features of patients and construct a radiomic model for predicting the diagnosis and treatment response of pituitary adenomas

Eligibility criteria:
inclusion criteria: 1. gender unlimited, 18-80 years old; 2. clinical diagnosis of pituitary adenoma and receive surgical treatment; 3. received brain imaging; 4. informed consent signed exclusion criteria: 1. pregnant / lactating women 2. contraindications of imaging examination 3. lack of effective clinical data 4. mri data before treatment cannot be obtained 5. postoperative pathology not revealed pituitary adenoma
effects of local anesthesia on post-operative pain during laparoscopic inguinal hernia repair

Conditions: Post Operative Pain (Post Laparoscopic Hernia Repair)

Summary: to assess effect of local anesthetic into the preperitoneal space during laparoscopic hernia repair on post-operative pain.


Eligibility criteria:
inclusion criteria: * age 18 or older with unilateral or bilateral inguinal herna for laparoscopic repair * american society of anesthesiology (asa) class i and ii exclusion criteria: * conversion from laparoscopic to open surgery * history of chronic pain or ongoing treatment for chronic pain * age less than 18 yrs * allergy to local anesthetics

Keywords: post operative pain hernia repair
impact of acute normovolemic hemodilution on blood viscosity

Conditions: Ischemic Heart Disease; Coronary Artery Disease

Summary: acute normovolemic hemodilution (anh) has long been employed for reducing allogenic blood transfusion for cardiac surgery, and hydroxyethyl starch has been used as an intravenous replacement fluid during anh procedure. however, possible impact of anh employing hes on blood viscosity and oxygen delivery have not been well investigated in patients undergoing off-pump coronary artery bypass (opcab) surgery . anesthesia is induced and maintained by using propofol-remifentanil-rocuronium in opcab surgery (n=21). anh is performed by using 5 ml/kg of blood salvage and administering 5 ml/kg of balanced hes 130/0.42 (tetraspan™) for 15 min during vascular graft harvesting. for the present study, three arterial blood samples (3 ml each) are taken before (sample 1) and after anh (sample 2 and 3) and they are stored in 3 tubes. sample 3 (in tube) undergoes further 30% in-vitro dilution by adding 1-1.5 ml hes. by using a scanning capillary tube viscometer (hemovister™), blood viscosity at low shear rate (5/sec) of the three samples are determined. by using a formula with blood viscosity and hematocrit, tissue o2 delivery index (todi, = hematocrit/viscosity at 5/sec) is calculated.


Eligibility criteria:
inclusion criteria: * patients undergoing off-pump coronary artery bypass graft surgery exclusion criteria: * preoperative anemia * lv ejection fraction \< 50%

Keywords: acute normovolemic hemodilution coronary artery bypass graft surgery hydroxyethyl starch blood viscosity
randomized, controlled trial to test the efficacy of interferon beta in the treatment of intermediate uveitis

Conditions: Uveitis, Intermediate; Macular Edema; Multiple Sclerosis

Summary: the purpose of this study is to investigate if interferon beta is superior to the standard treatment with methotrexate for the treatment of intermediate uveitis and macular edema.

deuter et al were the first to show the anti-edematous effect of interferon alpha on inflammatory macular edema (deuter c. m. e., kötter i., günaydin i., zierhut m. treatment of the cystoid macular oedema in behçet's disease with interferon alfa-2a, retina, in press). in an interventional, multi-centric pilot-study we could demonstrate a positive effect of interferon beta on ed associated uveitis, especially in reducing the macular edema. undesired effects of the treatment were not observed. thus we want to test the efficacy and safety of interferon beta compared to standard treatment with methotrexate in a prospective, clinically controlled trial on patients who suffer from intermediate uveitis with inflammatory macular edema who either have associated ed or have no systemic disease association, i.e. primary uveitis. .

Eligibility criteria:
inclusion criteria: * male and female patients age 18 and over * active uni- or bilateral non-infectious intermediate uveitis of at least 1 year duration * visual acuity on the worse eye at least 0.1 (20/200) and maximally 0.6 (20/30) caused by macular edema, defined by foveal thickness ≥ 250 µm * either primary uveitis or diagnosis of multiple sclerosis * previous treatment with oral corticosteroids in a dose of 0.5 mg per kg bodyweight of prednisone equivalent without sufficient success * previous treatment with other immunosuppressive drugs is facultative exclusion criteria: * exclusively anterior uveitis * absence of macular edema * optic nerve atrophy after neuritis nervi optici * peri-or intraocular injection of corticosteroids in the previous 3 months * allergies against any interferon * depression diagnosed by a psychiatrist * hepatic disease * infectious uveitis * other auto-immune diseases but ms * pregnancy, lactation * lack of reliable contraception * patients with metabolic, psychiatric or neoplastic diseases * active diseases like asthma, psoriasis or inflammatory bowel disease who have to be treated with corticosteroids * primary or secondary immune deficiency * tuberculosis or other infectious lung diseases * hepatitis b or c * life vaccination during the trial duration

Keywords: uveitis macular edema interferon multiple sclerosis encephalomyelitis disseminata (ed)
an observational study of avastin (bevacizumab) in combination with paclitaxel in first-line treatment in patients with her2-negative metastatic breast cancer

Conditions: Breast Cancer

Summary: this prospective observational study will evaluate the use in clinical practice, efficacy and safety of avastin (bevacizumab) in combination with paclitaxel in first line in patients with her2-negative metastatic breast cancer. data will be collected from eligible patients for up to 2.5 years.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * locally recurrent or metastatic breast cancer * no prior treatment for metastatic or locally recurrent disease * eastern cooperative oncology group (ecog) performance status 0-2 exclusion criteria: * history or clinical evidence of brain metastases * pregnancy * uncontrolled hypertension ( systolic \> 150 mmhg and/or diastolic \> 100 mmhg) or clinically significant (i.e. active) cardiovascular disease * major surgical procedure or significant traumatic injury within 28 days prior to enrolment
tolerability of alk grass tablet in children

Conditions: Allergy

Summary: the purpose of this trial is to assess whether the alk grass tablet treatment is safe to use in children aged 5-12 years


Eligibility criteria:
inclusion criteria: * grass pollen induced rhinoconjunctivitis * boys and girls, 5-12 years of age * positive skin prick test to grass pollen exclusion criteria: * severe asthma * previous treatment with immunotherapy
an observational study evaluating therapy optimisation using high-frequency and high-dosage administration of interferon-beta (rebif®) in multiple sclerosis (ms) patients

Conditions: Relapsing-Remitting Multiple Sclerosis

Summary: this was an observational, single arm, multicentric study conducted for the adjustment of treatment strategy and its monitoring using high-frequency and high-dosage administration of interferon-beta (rebif) in ms subjects. study focussed on assessment of the effectiveness and safety of existing immunomodulatory basis therapy in ms subjects.

treatment of ms, which progresses to attacks or episodes, with interferon-beta has established itself as therapy of the first choice. on the basis of different studies, the hypothesis was substantiated that the effectiveness is dependent on dose and application frequency. these realizations justify the use of high-dose interferon-beta not only in subjects in the initial stages of disease, but also in those subjects, who have a progressing disease activity even in the advanced stage, if other therapies fail. for achieving maximum benefit for the subject, an optimum therapy is imperative. the therapy plan (immunomodulatory therapy) of "ms therapy consensus group" (mstkg) is being widely used. in the article: "optimising lmmunomodulatory therapy for ms patients" that appeared in the "international journal of ms care" in the year 2002, a simple 9-scale model" is proposed that defines four areas respectively: not conspicuous, conspicuous, alarming and measures are necessary, in the three areas: attacks/episodes, disease progression and magnetic resonance tomography (mrt). the modification of an existing therapy, such as modifying the application plan, increasing the dosage, or substance change is recommended, if 'conspicuousness' is shown in all three areas, two areas are shown as 'alarming' or an area is shown as 'action necessary'. the decision for a therapy adjustment with the help of the "three scale model" should not happen solely on the results of the mrt. the model in the study involved attack or episode pertaining to: frequency, degree of severity, ability of involution and the response to a cortisone pulse therapy. objectives * to assess the effectiveness and safety of existing immunomodulatory basis therapy in ms subjects * to identify candidates suitable for possible therapy adjustment

Eligibility criteria:
inclusion criteria: * subjects with clinically ensured diagnosis of a ms and history of attacks or episodes * subjects who were on one of the permitted basis therapies at least since 6 months * subjects with existing systemic concurrent diseases (e.g.diabetes, heart, liver, kidney diseases) should be monitored very carefully. exclusion criteria: * subjects with secondary progressive course of the ms without attacks or episodes, pregnant or nursing subjects as well as subjects with history of contraindications

Keywords: multiple sclerosis rebif interferon
effect of exogenous ketosis during ultra-endurance exercise

Conditions: Exercise; Ultra-endurance Running; Ketosis; Skeletal Muscle; Cognitive Function

Summary: the aim of this study is to investigate the effect of oral ketone administration during and immediately after an ultramarathon. potential changes in cognitive function (reaction time, number of errors), running performance, jump height, skeletal muscle inflammatory infiltration and hormonal alterations will be the main focus. in this context, subjects (n=24) will perform a 100km ultrarunning trail, while receiving either ketone ester (ke, n =12) or placebo (con, n=12). experimental measurements will be performed immediately before and after the ultramarathon as well as 24h after the ultramarathon.


Eligibility criteria:
inclusion criteria: * males between 18 and 55 years old * recreational or competitive runner having performed an ultramarathon (\>42km) during the last 2 years * good health status confirmed by a medical screening * body mass index (bmi) between 18 and 25 exclusion criteria: * any kind of injury/pathology that is a contra-indication to perform ultra-endurance exercise * intake of any medication or nutritional supplement that is known to affect exercise performance * intake of analgesics, anti-inflammatory agents, or supplementary anti-oxidants, from 2 weeks prior to the start of the study. * blood donation within 3 months prior to the start of the study * smoking * more than 3 alcoholic beverages per day * current participation in another research trial * any other argument to believe that the subject is unlikely to successfully complete the full study protocol * adherence to a high-fat, low-carbohydrate ketogenic diet (less than 20% of energy intake derived from carbohydrates)
clinical use of pathogen reduced red blood cell suspension

Conditions: Oncologic Disorders; Hematologic Diseases

Summary: the aim of the study is to evaluate the effectiveness and safety of the application of pathogen inactivated rbc suspension in children with oncological and hematological diseases.

assumed scope of study: the study will include 70 patients: 35 patients to the test group, who will get transfusions with pathogen-inactivated red blood cell suspension; 35 patients to the control group, who will get transfusions with irradiated red blood cell suspension. methods: * selection of patients suitable to participate in the study. * a few days before the assumed transfusion date, select/prepare a red blood cell suspension corresponding to abo and rh systems, with no more than 14 days of storage. conduct direct antiglobuline test (dat), indirect antiglobuline test (iat) and test for individual compatibility with the patient's serum. * before performing transfusion (on the day of transfusion), determine the initial indices of the patient (hb, hct, haptoglobin). determine the red blood cell suspension indices (hb, hct, extracellular potassium, free hemoglobin, hemolysis percentage). * perform transfusion. evaluate the presence and severity of post-transfusion reactions and complications. * measure the patient's hb, hct, potassium and haptoglobin levels the next day after the transfusion. * perform dat 3 to 5 five days after the transfusion. * perform iat 2 to 3 weeks after the transfusion. * evaluate the need for transfusions over the follow-up period (30 days).

Eligibility criteria:
inclusion criteria: patients who need supportive transfusion therapy with rbc suspension exclusion criteria: * active bleeding * sepsis/severe infection (any infectious disease requiring pressor agents, infusion and respiratory support) * positive dat and / or iat before transfusion * double populations for abo and rh blood group antigens * severe hepatomegaly/splenomegaly * patients receiving chemotherapy (at the time of need for transfusion) * patients receiving antithymocyte immunoglobulin and also within 7 days after its completion * patients requiring transfusion of only irradiated blood components

Keywords: patogen inactivation pathogen reduction clinical use riboflavin+uv rbc transfusion whole blood
effect of budesonide / formoterol combination in repeated amp provocations

Conditions: Asthma

Summary: the aim is to study whether the budesonide component within the budesonide/ formoterol combination inhaler has additive value in a model of "slow onset acute asthma" , namely three amp provocation tests performed on one day


Eligibility criteria:
inclusion criteria: * asthma diagnosis according to ats criteria, * lung function (fev1) above 60% of predicted, * amp-pc20 below 160 mg/ml with a documented fall in fev1 of 30% in this provocation test exclusion criteria: * having smoked \> 10 pack-years, * hypersensitivity to one of the study drugs, * significant co-morbidity, pregnancy or lactating
safety and tolerability of al-001 ophthalmic injection in subjects with wamd

Conditions: Wet Age-related Macular Degeneration (wAMD)

Summary: this phase i/iia study is designed to evaluate the safety, tolerability, preliminary pharmacodynamics and pharmacokinetics in patients with wet age-related macular degeneration. eligible patients, who meet the inclusion/exclusion criteria and have shown an anatomic response to an anti-vegf (vascular endothelial growth factor) injection, will receive a single dose of al-001 administered via suprachoroidal space injection.


Eligibility criteria:
inclusion criteria: 1. age≥ 50 and ≤ 80. 2. the study eye was diagnosed with subfoveal active choroidal neovascularization (cnv) lesions secondary to wamd. 3. best corrected visual acuity (bcva) of study eye during screening, early treatment of diabetic retinopathy study (etdrs) letters≤73 and ≥19. 4. the subject or their legal representative agrees to participate in this study and signs a written icf. exclusion criteria: 1. non-wamd induced cnv or macular edema in the study eye. 2. non-wamd induced eye conditions that may affect central vision or medical history that may seriously affect central vision in the study eye. 3. uncontrolled glaucoma in the study eye. 4. history of vitreoretinal surgery, antiglaucoma trabeculectomy, or other anti-glaucoma filtering surgery in the study eye. 5. refractive interstitial opacity that significantly affects visual function assessment or fundus examination in the study eye. 6. ametropia (high myopia or high hyperopia) \> 8.0d in the study eye, or significant posterior scleral staphyloma in the study eye. 7. malignant tumor in any eye, including but not limited to eye lymphoma or choroidal melanoma. 8. none of intraocular inflammation in the study eye. 9. other conditions that may affect compliance or may not be suitable to participate in this trial in the opinion of investigator.